|1.||Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
|2.||Nervous System Diseases (Neurological Disorders)
|3.||Parkinson Disease (Parkinson's Disease)
|1.||Sobue, Gen: 33 articles (12/2015 - 03/2003)|
|2.||Katsuno, Masahisa: 26 articles (12/2015 - 03/2003)|
|3.||Tanaka, Fumiaki: 26 articles (05/2013 - 06/2004)|
|4.||Adachi, Hiroaki: 18 articles (12/2015 - 03/2003)|
|5.||Trojanowski, John Q: 16 articles (01/2012 - 09/2004)|
|6.||Suzuki, Keisuke: 15 articles (11/2012 - 03/2006)|
|7.||Banno, Haruhiko: 15 articles (11/2012 - 03/2006)|
|8.||Lee, Virginia M-Y: 15 articles (01/2012 - 09/2004)|
|9.||Brown, Robert H: 11 articles (01/2014 - 04/2003)|
|10.||Minamiyama, Makoto: 11 articles (07/2013 - 03/2003)|
|1.||Biological Markers (Surrogate Marker)IBA
03/25/2011 - "The establishment of novel disease-specific biomarkers of motor neuron disease might be helpful in the design of improved diagnostic tools and the identification of novel therapeutic targets."
09/01/2011 - "New data suggest that prognostic accuracy may be improved in motor neuron disease using protein biomarkers for neurodegeneration. "
04/01/2010 - "The application of biomarkers in clinical trials for motor neuron disease."
06/01/2000 - "PET has been used as a tool in the study of patients with motor neuron disease (MND) for well over ten years now, but its potential in diagnosis and to identify surrogate markers of disease expression (phenotype) and progression has yet to be fully realized. "
10/01/2014 - "These unprecedented findings in ALS and PLS fibroblasts could shed new light onto disease pathogenesis and help in developing biomarkers to predict disease evolution and the individual response to therapy in motor neuron diseases."
05/01/1990 - "Recent studies reported the presence of anti-ganglioside antibodies in occasional patients with motor neuron disease. "
02/15/2014 - "Association of a paraneoplastic motor neuron disease with anti-Ri antibodies and a novel SOD1 I18del mutation."
10/01/2011 - "Anti-Ma2/Ta antibodies in a woman with primary lateral sclerosis-like phenotype and Sjögren syndrome."
08/01/2010 - "In these three patients, all with anti-Hu antibodies, the second episode consisted of a lower motor neuron disease. "
08/01/2007 - "Absence of paraneoplastic antineuronal antibodies in sera of 145 patients with motor neuron disease."
|3.||Ciliary Neurotrophic Factor (CNTF)IBA
03/01/1999 - "The differential efficacy of peripheral and central CNTF vector administrations might be of interest for future studies in human motor neuron diseases."
08/01/1994 - "In the present study we tested the effects of recombinant rat or human ciliary neurotrophic factor in the wobbler mouse model of motor neuron disease. "
08/01/1996 - "This result supports suggestions that CNTF deficiency may be an important factor in the development of motor neuron disease."
08/01/1996 - "Decreased CNTF appears be associated with primary motor neuron disease rather than a generalized process of axon loss. "
08/01/1996 - "Immunoperoxidase staining showed reduced CNTF expression in nerves of patients with motor neuron disease but not in patients with diabetic motor neuropathy. "
11/01/2014 - "Motor difficulties associated with FTD may present with parkinsonian symptoms or motor neuron disease, for which riluzole is indicated as therapy. "
04/10/2013 - "The critical biochemical target of riluzole in motor neuron disease is not known, but the pharmacological targets of riluzole include SK channels. "
06/01/2006 - "Audit of outcomes in motor neuron disease (MND) patients treated with riluzole."
03/01/2005 - "Riluzole is used in a fixed dosing schedule of 50 mg twice daily to treat patients with amyotropic lateral sclerosis (ALS), one form of motor neurone disease. "
11/01/2004 - "A diagnosis of possible motor neuron disease was made and the patient was commenced on riluzole. "
09/01/2007 - "Paradoxically, evidence from studies on the legs at odd angles (Loa) mouse and a transgenic mouse model for human motor neuron disease suggest that partial limitation of the function of dynein may in fact lead to improved axonal transport in the transgenic mouse, leading to delayed disease onset and increased life span."
06/11/2010 - "The legs at odd angles (Loa) mutation in cytoplasmic dynein ameliorates mitochondrial function in SOD1G93A mouse model for motor neuron disease."
08/20/2007 - "These findings are consistent with studies indicating that perturbations in dynein activity can contribute to the aberrant accumulations of neurofilaments that accompany ALS/motor neuron disease."
06/01/2011 - "Mice with mutation in dynein heavy chain 1 do not share the same tau expression pattern with mice with SOD1-related motor neuron disease."
01/01/2009 - "Altogether, these findings show that dynein heavy chain mutation triggers sensory neuropathy rather than motor neuron disease."
|6.||Brain-Derived Neurotrophic Factor (BDNF)IBA
11/01/2011 - "These results suggest that manipulation of BDNF/TrkB signaling might have therapeutic efficacy in motor neuron diseases."
04/01/1995 - "In this study, we examined the effects of exogenous BDNF on the progression of wobbler mouse motor neuron disease (MND). "
04/01/2001 - "Brain-derived neurotrophic factor (BDNF) is neuroprotective for motoneurons undergoing degeneration, including those in natural motor neuron disease (MND) in wobbler mice. "
04/01/2001 - "Role of brain-derived neurotrophic factor in wobbler mouse motor neuron disease."
06/01/1996 - "These findings show that BDNF and NT-3 are survival factors for adult rat CSN in vivo, and may contribute to the development of therapeutic strategies aiming at the prevention of CSN degeneration in human motor neuron diseases."
|7.||Proteins (Proteins, Gene)IBA
01/01/1989 - "This information may be helpful in selecting an animal species for further investigation of the role of M-proteins in motor neuron disease."
06/01/2008 - "In this review, we integrate results from studies of yeast, fly and mammalian VAPs that provide insight into the structural features of these proteins, the network of VAP-interacting proteins, their possible physiological functions, and their involvement in motor neuron disease."
01/01/2014 - "Cell to cell spreading of misfolded proteins as a therapeutic target in motor neuron disease."
12/01/2013 - "Commentary: multifactoriality of amytrophic lateral sclerosis: linking unfolded proteins to oxidative stress in microglia."
01/01/2012 - "Mutation of which causes ER stress and motor neuron disease, making it important to determine which proteins bind VAP. "
|8.||Glutamic Acid (Glutamate)FDA Link
08/01/1995 - "This system provides a preclinical screening method for the burgeoning number of drugs postulated for clinical trials in motor neuron disease and a model to evaluate the mechanisms of chronic glutamate toxicity."
05/01/2003 - "Furthermore, there is evidence of altered glutamate uptake and catabolism in motor neuron diseases. "
12/01/2002 - "There is strong evidence that a complex interplay between oxidative stress, mitochondria abnormalities and alteration of glutamate neurotransmission plays an important role in the pathogenesis of motor neuron diseases. "
05/25/1998 - "Blood glutamate levels in patients with motor neuron disease."
06/01/1995 - "CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients."
07/15/2014 - "These gangliosides as well as GM1 were tested in 655 sera obtained from patients who were suspected of having amyotrophic lateral sclerosis or motor neuron disease to find a treatable condition. "
01/13/1984 - "Gangliosides of healthy and pathologic muscles (amyotropic lateral sclerosis and facio-scapulo-humeral muscular dystrophy) were studied. "
10/01/1983 - "A therapeutic trial of gangliosides and thymosin in the Wobbler mouse model of motor neuron disease."
11/01/1992 - "The gangliosides GM1 and GD1b have recently been reported to be potential target antigens in human motor neuron disease (MND) or motor neuropathy. "
12/01/1988 - "Immunostaining of motor nerve terminals by IgM M protein with activity against gangliosides GM1 and GD1b from a patient with motor neuron disease."
|10.||Histone Deacetylase InhibitorsIBA
01/01/2008 - "In this review, we discuss recent developments in dissecting the mechanism of action of HDAC inhibitors (HDACi) as a new group of mechanism-based drugs for motor neuron diseases, together with current progress in understanding their clinical application. "
01/01/2008 - "Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases."
02/01/2008 - "Based on the promising in vitro and in vivo analyses, clinical trials have been initiated to evaluate the safety and efficacy of HDAC inhibitors for the treatment of devastating diseases such as Huntington's disease, amyotropic lateral sclerosis and spinal muscular atrophy. "
04/01/2006 - "Recently, HDAC inhibitors have been found to ameliorate progression of the spinal muscular atrophy (SMA) motor neuron disease and the Huntington disease mouse models. "
04/01/2009 - "Sodium phenylbutyrate, a histone deacetylase inhibitor, improves transcription and post-transcriptional pathways, promoting cell survival in a mouse model of motor neuron disease. "
06/01/1992 - "Ascertaining mast-cell distribution in biopsies may help to elucidate denervation effects in motor neuron disease."
01/01/2006 - "To study peculiarities of chronic partial denervation (CPD), needle electromyography (EMG) of the neck, upper and lower extremity muscles on the less affected side was performed in 25 patients with definite motor neuron disease (MND) and in 9 patients with benign motor neuron disorders (BMND) with 2-month-long follow-up interval. "
01/01/2006 - "[The study of denervation-reinnervation process in motor neuron disease and benign neuron disorders]."
01/01/2016 - "These results add to an emerging understanding that TSCs may play a role in motor terminal degeneration and denervation in animal models of motor neuron disease. "
01/01/2009 - "Denervation and reinnervation comprise a dynamic process that begins in the early periods of amyothrophic lateral sclerosis and lasts until the final individual motor neuron dies. "
|2.||Drug Therapy (Chemotherapy)
08/01/2008 - "A strategy for developing effective amyotropic lateral sclerosis pharmacotherapy: from clinical trials to novel pharmacotherapeutic strategies."
08/01/2008 - "In addition to finding effective therapies, research is also needed in order to detect early disease markers since pharmacotherapy is most beneficial when given early in the course of sporadic amyotropic lateral sclerosis."
06/01/2004 - "Chemotherapy delays progression of motor neuron disease in the SOD1 G93A transgenic mouse."
01/01/2015 - "Coupled to this structural diversity is the significant array of biological properties manifested by many of its members, of which their relevance in motor neuron disease and cancer chemotherapy has attracted considerable attention. "
01/01/2014 - "Furthermore, its promising pharmacological and phytochemical profiles have stimulated significant interest in the clinical realm, especially in the areas of cancer and motor neuron disease chemotherapy. "
|3.||Transplantation (Transplant Recipients)
05/02/2011 - "Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates motor neuron disease in SOD1 transgenic rats."
10/01/2011 - "Although many challenges and questions remain, the beneficial effects observed following transplantation therapy in animal models of motor neuron disease has sparked hope and a number of clinical trials. "
01/01/2014 - "In this review, we focused on evidence-based data on astrocyte replacement transplantation therapy using GRPs in animal models of motor neuron diseases. "
05/02/2011 - "Transplantation was done prior to the onset of motor neuron disease. "
11/01/2008 - "Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease."
07/01/2007 - "This study was performed to determine whether there are distinctive features to the pattern of muscle denervation in motor neuron disease. "
01/01/2009 - "Consistently, we did not observe electrophysiological or biochemical signs of muscle denervation, indicative of motor neuron disease. "
02/01/2007 - "The ITS-MUNE analysis method has the potential to quantitatively measure the progression of motor neuron diseases and therefore the efficacy of treatments designed to alleviate pathologic processes of muscle denervation."
02/01/2007 - "Weakness and atrophy are clinical signs that accompany muscle denervation resulting from motor neuron disease, peripheral neuropathies, and injury. "
01/01/2014 - "[Percutaneous endoscopic gastrostomy in a myotrophic lateral sclerosis. "
11/28/2012 - "To examine factors influencing percutaneous endoscopic gastrostomy (PEG) uptake and outcomes in motor neuron disease (MND) in a tertiary care centre. "
02/01/2012 - "A multidisciplinary approach embracing advances in non-invasive ventilation and gastrostomy can improve quality of life and extend the survival of motor neuron disease patients."
12/01/2010 - "Evaluation of two different methods for per-oral gastrostomy tube placement in patients with motor neuron disease (MND): PIG versus PEG procedures."
11/28/2012 - "Nutritional support teams increase percutaneous endoscopic gastrostomy uptake in motor neuron disease."